Design Therapeutics, Inc. DSGN Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $12.77M-24.2% | $16.86M+11.7% | $15.09M-23.4% | $19.7M+44.2% | $13.67M-39.4% | ||
| $210.05M+3.5% | $202.99M+6.3% | $190.88M-2.9% | $196.57M-9.0% | $216.01M-3.1% | ||
| $227.05M+1.5% | $223.78M+7.1% | $209.03M-4.9% | $219.79M-5.9% | $233.64M-5.8% | ||
| $824K-16.0% | $981K-11.1% | $1.1M-12.2% | $1.26M-8.6% | $1.38M-2.3% | ||
| $230.44M+1.9% | $226.2M+6.8% | $211.77M-5.0% | $222.89M-6.1% | $237.48M-5.8% | ||
| $2.28M-1.6% | $2.31M+20.9% | $1.91M+88.8% | $1.01M-68.1% | $3.18M+45.5% | ||
| $10.19M-21.9% | $13.06M+16.8% | $11.17M+27.7% | $8.75M+6.2% | $8.24M-2.7% | ||
| $12.39M-9.6% | $13.7M+13.7% | $12.05M+22.3% | $9.85M+3.1% | $9.56M-4.4% | ||
| $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | ||
| -$314.64M-5.9% | -$297.01M-5.7% | -$281.01M-6.4% | -$264.01M-7.8% | -$244.93M-7.8% | ||
| $218.05M+2.6% | $212.5M+6.4% | $199.72M-6.3% | $213.04M-6.5% | $227.92M-5.9% | ||
| $230.44M+1.9% | $226.2M+6.8% | $211.77M-5.0% | $222.89M-6.1% | $237.48M-5.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Design Therapeutics, Inc.'s total assets?
- Design Therapeutics, Inc. (DSGN) holds $230.4M in total assets, down 3.0% year over year.
- How much debt does Design Therapeutics, Inc. have?
- Design Therapeutics, Inc. carries $2.7M in total debt against $218.1M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Design Therapeutics, Inc. have?
- Design Therapeutics, Inc. holds $12.8M in cash and equivalents.
- Can Design Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 22.28 — current assets exceed current liabilities.
- Where does Design Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.